Aller au contenu principal
Accès ouvert déclaré 2026 article

The Effect of Food on the Pharmacokinetics and Gastrointestinal Tolerability of Bersiporocin, a Novel Oral Prolyl-tRNA-Synthetase Inhibitor

0Citations signalées, ce qui n’est pas une note de qualité
4Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : kr. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Purpose: Bersiporocin is a first-in-class prolyl-tRNA-synthetase inhibitor under clinical development for the treatment of idiopathic pulmonary fibrosis. In a prior first-in-human study, the incidence of gastrointestinal (GI) adverse events (AEs) differed across prandial conditions. This study aimed to evaluate the effect of food on the pharmacokinetics (PKs) and safety profile of bersiporocin. Patients and Methods: This randomized, open-label, single-dose, three-period crossover study enrolled 36 healthy Korean participants. Each participant received a single oral dose of bersiporocin 200 mg under three conditions: fasted (A), 30 minutes after a high-fat meal (B), and 2 hours after a high-fat meal (C), with a 7-day washout between periods. Plasma concentrations of bersiporocin and its active metabolite M8 were quantified using a validated LC-MS/MS assay, and PK parameters were determined by non-compartmental analysis. Safety was evaluated by monitoring AEs, clinical laboratory tests, vital signs, and electrocardiograms. Results: , was comparable across conditions, with geometric mean ratios (90% confidence intervals) of 0.9380 (0.8500-1.0351) and 0.9944 (0.9000-1.0988) for B and C relative to A, respectively. Similar PK trends were observed for M8. A higher incidence of GI AEs was observed in condition B (45.7%) than in conditions A (25.7%) or C (24.2%). Systemic exposure did not differ between participants with and without vomiting. Conclusion: A high-fat meal delayed the oral absorption rate of bersiporocin but did not have a clinically significant effect on systemic exposure to bersiporocin or M8. Given the increased incidence of GI AEs under early postprandial conditions, administration under fasted conditions or at least 2 hours postprandially may be appropriate for future clinical studies.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
The Effect of Food on the Pharmacokinetics and Gastrointestinal Tolerability of Bersiporocin, a Novel Oral Prolyl-tRNA-Synthetase Inhibitor
Date Crossref
01/07/2026
Éditeur
Informa UK Limited
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisRNA and protein synthesis mechanismsLung Cancer Treatments and Mutations

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.